Nuvation Bio Q3 revenue rises to $45.0 million; net loss narrows to $41.9 million
Nuvation Bio reported third quarter 2026 total revenue of $45.0 million, up from $13.1 million a year earlier, driven by $27.5 million in net product revenue from IBTROZI. The net loss narrowed to $41.9 million, or $(0.12) per share, from $55.8 million, or $(0.16) per share, a year earlier, while cash, cash equivalents and marketable securities were $663.4 million as of September 30, 2026. The filing gives no revenue or earnings guidance for future periods.
Key points
- Total revenue was $45.0 million for the quarter, versus $13.1 million in the third quarter of 2025.
- Net product revenue from IBTROZI was $27.5 million, an 18% quarter-over-quarter increase.
- Net loss was $41.9 million, or $(0.12) per share, compared with $55.8 million, or $(0.16) per share, a year earlier.
- Research and development expenses rose to $32.7 million from $28.8 million, and SG&A expenses rose to $42.6 million from $37.4 million.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.